Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune Inc's focus on chronic inflammatory diseases positions the company favorably, with promising initial results from its pipeline products, particularly EVO756 and EVO301. The expansion into additional indications, such as ulcerative colitis, could significantly enhance revenue potential, as the market demonstrates a strong appetite for innovative therapeutic mechanisms. Furthermore, early Phase 2 results in conditions like atopic dermatitis indicate a substantial long-term commercial opportunity, especially with a first-mover advantage in the IL-18 therapy space.

Bears say

Evommune Inc's stock outlook is negatively impacted by slower-than-anticipated market uptake of its pipeline products, EVO756 and EVO301, primarily due to increased competition and potential hurdles to market access. Additionally, the company's projected peak sales may be significantly reduced as these therapies face challenges against existing treatment options, compounded by risks associated with patent challenges and possible generic erosion. Furthermore, there are concerns about medium- to long-term equity dilution risks, which could further strain financial stability and investor confidence.

Evommune Inc (EVMN) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 6 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.